Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

ated to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Financial tables follow

                                      InterMune, Inc.
               PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                   (unaudited, in thousands, except per share amounts)

                                      Three Months Ended      Six Months Ended
                                        
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Follow us on LinkedIn ... the world has attracted diverse players including academic ... The early years of nanotechnology development was dominated ... the high risks involved, which deterred private and ... evolving technology have been growing over the years, ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 ... engaged in the development of high-value and difficult to ... will be presenting at the 21 st Annual ... New York . Bertrand Liang , chief ... the company,s development programs and business strategy on Friday, ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it has filed a shelf registration statement on Form ... when declared effective by the SEC, will allow Poniard ... to $60 million aggregate amount of its common stock, ...
... Fate Therapeutics, Inc. announced today ... owned by Children,s Hospital Boston and Massachusetts General Hospital. ... supporting hematopoietic stem cells. These proprietary technologies developed ... Program at Children,s Hospital Boston and a scientific founder ...
... CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China,Biologic ... or the,Company,), one of the leading plasma-based pharmaceutical ... announced that the Company,s,management will present at the ... in New York, NY on May 18, 2009 ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4
(Date:9/18/2014)... Colo., USA A new GSA Bulletin ... the lower Rio Puerco and Chaco Wash in northern ... rings from salt cedar and willow, investigators were able ... or greater. They then combined this data with aerial ... the history of these arroyos. , Arroyos are deep, ...
(Date:9/18/2014)... McGill University and the Quebec government have discovered ... Canadian Journal of Fisheries and Aquatic Sciences . ... cleansers, or industrial cleansers, to which they are ... size and buoyancy, they may readily pass through ... contaminant in the world,s oceans, but have only ...
(Date:9/18/2014)... information is stored in DNA, tiny strands of nucleic ... bodies. To express this genetic data, our DNA is ... into proteins that perform tasks in our cells. ... of RNA molecule. Unlike all other known RNAs, this ... circRNA molecules are abundant, little has been known about ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... of organic produce increases with consumers, growers need more ... and Gary R. Cline (retired) of the Land Grant ... designed to investigate options for reducing the presence of ... roots, shoots, and flowers, and transmit the bacterial wilt ...
... and the Society for Mycotoxin Research have signed an ... , the official journal of the Society. Aimed ... the journal deals with all topics related to mycotoxins, ... issue will appear in March 2009. High-quality original ...
... a $2.9 million, three-year grant from the Minerals Management ... at Austin marine scientists will assess the biological and ... before the area opens for offshore oil drilling. ... Interior) brings together several highly experienced Arctic scientists from ...
Cached Biology News:Controlling cucumber beetles organically 2Mycotoxin Research joins Springer's life sciences journals program 2Marine scientists to assess environment before offshore drilling begins in US arctic waters 2Marine scientists to assess environment before offshore drilling begins in US arctic waters 3
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Biology Products: